Objective. Evaluate aberrant drug-related behaviors in patients administering fentanyl buccal tablet or traditional short-acting opioids for breakthrough pain. 
Introduction
Opioids are widely used for the treatment of moderate to severe chronic, persistent pain [1] [2] [3] . Inappropriate use of prescription opioids is a growing problem that can complicate pain management and lead to misuse, abuse, diversion, addiction, and other serious problems [4, 5] . Aberrant behavior is defined as drugseeking behavior and/or problematic opioid use and is sometimes associated with addictive disease [6] . In studies of real-world patients with chronic pain who were monitored for 1 year, opioid misuse or aberrant behaviors occurred in 32-41% [4, 7] .
Information on the misuse, abuse, addiction, or diversion of opioids in the clinical study setting is limited. The majority of data published to date is from the clinical practice setting. A need exists for additional information on methods to identify and predict the risk of aberrant drugrelated behaviors before and after initiation of opioid therapy to help guide appropriate clinical use of these agents [8] .
Fentanyl buccal tablet is a rapid-onset opioid indicated for the management of breakthrough pain (BTP) in cancer patients who are opioid tolerant [9, 10] . A randomized, double-blind, active-controlled crossover study with a 12-week open-label extension period evaluated the efficacy and safety of fentanyl buccal tablet vs a traditional short-acting opioid (immediate-release oxycodone) in opioid-tolerant patients with chronic pain who were experiencing BTP [11] . Treatment with fentanyl buccal tablet was associated with a rapid onset of analgesia, with significant differences in pain intensity as early as 10 minutes and in any pain relief as early as 15 minutes postdose [11] . After the 12-week open-label treatment extension phase, patients and clinicians reported consistently better functional improvement and satisfaction with fentanyl buccal tablet than with traditional short-acting opioids [12] .
Various factors are involved in the assessment of risk of abuse and misuse. Limited data suggest that a faster rate of increase in blood levels may contribute to greater drug abuse liability [13] . However, there have been no controlled studies in chronic pain to support this theory. It is believed that many other factors, such as genetic predisposition (specific opioid receptor binding/ interaction features and other neurobiological factors that influence behavior), dose, patient history, and environment, may also have an impact on abuse or misuse [14] .
The objective of this analysis was to evaluate and compare occurrences of aberrant drug-related behaviors in patients administering fentanyl buccal tablet or a traditional oral short-acting opioid for BTP over 12 weeks of open-label treatment. The value of pretreatment risk assessment was also investigated.
Methods

Study Design and Patients
Opioid-tolerant patients with chronic pain who completed the randomized, double-blind, active-controlled, crossover portion of the study comparing the efficacy and safety of fentanyl buccal tablet (FENTORA/EFFENTORA, Teva Pharmaceuticals, Frazer, PA, USA) with immediaterelease oxycodone for BTP were eligible to enroll in this 12-week open-label extension period. Details of the study design and primary results have previously been reported [12] . The study was conducted at 42 sites in the United States from December 2008 to November 2009 (http:// www.ClinicalTrials.gov, NCT00813488). The protocol was approved by an institutional review board or independent ethics committee at each study site, and all study procedures were conducted in accordance with good clinical practice [15] . Written informed consent was obtained from all patients before study enrollment.
Men and women between 18 and 80 years of age were eligible for the study if they 1) had a ≥3 months history of chronic pain; 2) were opioid tolerant (i.e., were taking at least 60 mg/day of oral morphine or the equivalent of another opioid as an around-the-clock opioid for ≥1 week before study entry); 3) had an average pain intensity score of ≤6 on an 11-point numeric rating scale (0 = no pain, 10 = worse pain imaginable); and 4) were experiencing one to four episodes of BTP per day (lasting <4 hours on average) and were achieving at least partial relief with opioids for their BTP. Patients with uncontrolled or rapidly escalating pain that was not BTP or with a recent history (≤5 years) of substance abuse were excluded from the study [11, 12] .
Patients entering the open-label extension period were randomized to continue treatment with fentanyl buccal tablet at the successful dose identified during the previous double-blind portion of the study or to begin treatment with any traditional short-acting opioid, as determined for each patient to be the standard of care by their treating physician. Patients randomized to fentanyl buccal tablet were not permitted to use any other supplemental medication but were allowed to take a second dose of fentanyl buccal tablet if, after 30 minutes, relief of the BTP episode was insufficient. Patients were instructed to treat no more than six BTP episodes per day with no more than eight doses of fentanyl buccal tablet per day. Patients randomized to a traditional short-acting opioid were permitted to take any supplemental medication prescribed by their physician (with the exception of oral transmucosal fentanyl citrate and fentanyl buccal tablet). Patients in both treatment groups continued administering their around-the-clock medication throughout the study. Around-the-clock medication could have been changed at any time during the open-label extension period if clinically indicated.
Several risk management strategies were employed in the study. Study medication was counted at visits 7, 8, and 9, and investigators were responsible for maintaining drug accountability records. Urine drug screenings were performed at screening and at each visit during the openlabel extension period (visits 6, 7, 8, and 9), as well as unannounced at any time during the study at the discretion of the investigator.
Assessments
The Screener and Opioid Assessment for Patients With Pain-Revised (SOAPP-R) was used to assess the effectiveness of screening for each patient's risk of developing an aberrant drug-related behavior at baseline of the overall study. The questionnaire consists of 24 questions that address eight concepts: substance abuse history, medication-related behaviors, antisocial behaviors/history, psychosocial problems, psychiatric history, doctor-patient relationship factors, emotional attachment to pain medications, and personal care and lifestyle issues [16] . Patients rated answers on a 5-point scale (0 = never, 1 = seldom, 2 = sometimes, 3 = often, and 4 = very often), with the total possible score ranging from 0 to 96. Scores ≥18 were used to classify patients at potentially higher risk for an aberrant drug-related behavior [16] .
The Addiction Behaviors Checklist (ABC) was used to evaluate aberrant behaviors and behaviors characteristic of addiction related to prescription opioid medications [17] . Investigators completed the ABC at baseline and visits 6, 7, 8, and 9 (final visit, week 12, or upon early termination of the study). The ABC total score was calculated using the 20 items on the checklist. Each affirmative response was counted as 1 point, and the total score could range from 0 to 20. Patients with a total score ≥3 were classified as exhibiting inappropriate medication use during the study.
The Current Opioid Misuse Measure (COMM) was also used to evaluate aberrant behaviors [18] . Patients completed the COMM at baseline and visits 6, 7, 8, and 9 (final visit). Answers to the 17 questions on the COMM were rated on a 5-point scale (0 = never, 1 = seldom, 2 = sometimes, 3 = often, and 4 = very often), with the total score ranging from 0 to 68. Patients with a total score ≥9 were classified as exhibiting aberrant drug-related behavior.
To determine the relationship between aberrant drugrelated behaviors and prospective risk assessment, the ABC and COMM scores were analyzed at the final visit of the open-label extension period according to SOAPP-R scores at baseline.
Occurrences of clinically documented aberrant behaviors (e.g., positive urine drug screening results, lost or stolen study medication) [7, [19] [20] [21] also were identified through a retrospective review of data from case report forms.
Statistical Analysis
The open-label safety analysis set, which included all patients who administered at least one dose of the study medication during the open-label extension period, was used for all aberrant behavior analyses. Data for the SOAPP-R, ABC, and COMM were summarized using descriptive statistics. To determine the utility of prospective risk assessment for the prediction of actual aberrant drug-related behaviors, Pearson's two-sided chi-squared test was used to test the change from baseline for ABC and COMM total scores (categorized) at each visit for patients whose baseline SOAPP-R total score was <18 and ≥18, separately.
Results
Patient Disposition and Demographics
A total of 131 patients entered the open-label extension period. Of these, 130 (99%) received treatment (fentanyl buccal tablet, N = 65; traditional short-acting opioid, N = 65) and were included in the safety analysis set, and 112 (85%) completed the open-label extension period (fentanyl buccal tablet, N = 53; traditional short-acting opioid, N = 59). The majority of patients (68%) randomized to a traditional short-acting opioid received immediaterelease oxycodone.
Patient demographics and other baseline characteristics, which are summarized in Table 1 , were generally similar between treatment groups. The traditional short-acting opioid group had a slightly greater percentage of men (45% vs 38%) and a slightly lower age (49.4 vs 51.8 years), both potential predictors of increased risk of aberrant drug-related behavior. On the other hand, the fentanyl buccal tablet group had a greater percentage of patients at baseline with a COMM score ≥9 (16% vs 9%), as well as a greater percentage of patients with a baseline SOAPP-R score ≥18 (29% vs 23%). Thus, overall, at baseline, it does not appear that one group was at a clearly higher risk for aberrant drug-related behaviors. 
Aberrant Behavior Assessments
The mean total SOAPP-R score in the safety analysis set was 14.0 (range 2.0-43.0), with a mean (standard deviation) SOAPP-R score of 14.4 (8.5) in patients administering fentanyl buccal tablet and 13.6 (7.4) in patients administered a traditional short-acting opioid. The majority of all patients in the study (74%) had an SOAPP-R score <18. The distribution of the SOAPP-R scores using this cutoff value was similar when comparing patients administering fentanyl buccal tablet (71%) and those administering a traditional short-acting opioid (77%).
Overall, the mean total ABC score at the final visit was 0.2 (range 0-4), and the mean total COMM score was 3.5 (range 0-23). No clinically meaningful changes in the ABC or COMM questionnaire total scores from baseline to endpoint were observed in either treatment group (Table 2) . No statistically significant differences between the fentanyl buccal tablet group and the traditional short-acting opioid group were observed; for total ABC score, the least squares (LS) mean difference between the fentanyl buccal tablet group and the traditional short-acting opioid group from baseline to endpoint was 0.01 (95% confidence interval [CI] −0.2, 0.3; P = 0.9), and for total COMM score, the LS mean difference was 0.54 (95% CI −0.7, 1.8; P = 0.4). The majority of patients had ABC scores <3 (96%) and COMM scores <9 (89%) at endpoint, suggesting that most patients did not exhibit aberrant drug-related behaviors at the end of the study.
The proportion of patients with ABC scores <3 and ≥3 by treatment and baseline SOAPP-R score and the proportion of patients with COMM scores <9 and ≥9 by treatment and baseline SOAPP-R score are summarized in Table 3 . There were no significant differences in the proportion of patients with ABC scores <3 and ≥3 and COMM scores <9 and ≥9 between treatment groups when stratified by baseline SOAPP-R scores <18 vs ≥18 (P ≥ 0.3). However, significantly more patients with baseline SOAPP-R score ≥18 had COMM score ≥9 at baseline (P < 0.0001) and endpoint (P = 0.03) ( Table 4) .
Aberrant behaviors were identified in 12 (18%) patients administering fentanyl buccal tablet and in 13 (20%) administering a traditional short-acting opioid. Two or more aberrant behaviors were identified for five patients (four administering fentanyl buccal tablet and one administering a traditional short-acting opioid). Five (42%) patients with aberrant behaviors administering fentanyl buccal tablet and two (15%) administering a traditional short-acting opioid had baseline SOAPP-R scores ≥18. One (8%) patient with aberrant behaviors administering fentanyl buccal tablet and one (8%) administering a traditional short-acting opioid had ABC scores ≥3 at baseline or the final visit. Four (33%) patients with aberrant behaviors administering fentanyl buccal tablet and two (15%) administering a traditional short-acting opioid had COMM scores ≥9 at baseline or the final visit.
Discussion
This 12-week, randomized, open-label extension period of a larger randomized, double-blind, crossover study pro- spectively evaluated the risk and incidence of aberrant drug-related behaviors in patients administering fentanyl buccal tablet vs a traditional oral short-acting opioid to treat BTP. There were no significant differences in ABC or COMM scores observed between treatment groups, indicating that aberrant drug-related behavior between fentanyl buccal tablet and traditional short-acting opioids was similar in this study population. Baseline SOAPP-R questionnaire scores were not predictive of aberrant drug use behaviors when evaluated by ABC and COMM scores at the final visit.
Despite this study's selective exclusion criteria, 26% (34/ 130) of enrolled patients in this analysis were considered at high risk for an aberrant behavior (SOAPP-R score ≥18).
Further, although the clinical study population was highly selected, aberrant drug-related behaviors occurred in 18% of patients administering fentanyl buccal tablet and 20% of patients administering a traditional short-acting opioid, highlighting the limitations of current screening methods and the need for active monitoring. Overall, the incidence of retrospectively analyzed aberrant drugrelated behaviors observed in this analysis was relatively low, which is consistent with findings from previous pooled analyses involving fentanyl buccal tablet. In a retrospective analysis assessing aberrant drug-related behaviors in 1,160 strictly selected predominantly noncancer patients administering fentanyl buccal tablet for BTP, <1% had an abuse-related event, <2% had a positive urine drug screening for an unprescribed drug or illicit substance, 1% had an event consistent with opioid overdose, and 11% had an aberrant behavior related to fentanyl buccal tablet [22] . However, this analysis generally included patients in open-label studies with no active control group. There have been no previous studies comparing the frequency of aberrant drug-related behaviors between rapid-onset opioids and traditional short-acting opioids. The current study found no clear signal that patients taking fentanyl buccal tablet had greater aberrant drug-related behaviors than those taking a traditional short-acting opioid.
Although clinicians may sometimes focus on the etiology of chronic pain (e.g., cancer related vs noncancer related) when determining the risk of aberrant drug-related behaviors [23] , assessing the pretreatment risk of aberrant behavior by SOAPP-R or other screening tools may have value [8] . In this study, a SOAPP-R score ≥18 at baseline was not predictive of an ABC score ≥3 but was associated with a COMM score ≥9. However, relatively fewer patients had an ABC ≥3, which may have limited the ability of this study to characterize the relationship between pretreatment SOAPP-R and ABC scores.
Particular attention to patient selection, including a thorough risk assessment, is necessary when initiating opioid therapy. Fentanyl buccal tablet must be used only for opioid-tolerant patients; thus, physicians should have a thorough understanding of the patient's history and potential risk factors before therapy with fentanyl buccal tablet is initiated. Proper patient selection could mitigate potential risks and enhance potential benefits associated with opioid therapy for chronic pain [14, 24] . In particular, clinical guidelines emphasize the value of risk stratification and close monitoring of patients for aberrant drug-related behaviors consistent with abuse, addition, or diversion [2] . Screening tools based on patient characteristics that assess the potential risks associated with chronic opioid therapy are likely to be helpful for risk stratification, but more studies are needed to understand how these tools may affect clinical outcomes [2, 8] . Additional assessment methods include urine drug testing, pill counts, family member or caregiver interviews, and review of prescription monitoring program data [2] .
This study had several limitations. The relatively small sample size may limit the strength of the conclusions, and the open-label study design, with no blinding for study investigators, may have led to bias in the results as it is possible that the investigator may have changed their management of an individual patient based on a low or high score on one of the risk measures employed during the study. Also, this investigation was performed in a controlled clinical study setting, with strict eligibility criteria. Importantly, patients with a recent history (≤5 years) of substance abuse were excluded from the overall study. Thus, these data may not be generalizable to the general clinical population. Patients with a high risk of substance abuse, as well as current substance abusers, would probably be at a greater risk for aberrant behaviors with a rapid-onset opioid such as fentanyl buccal tablet relative to a traditional short-acting opioid. The rate of aberrant drug-related behaviors in this carefully selected population was lower than that seen in previous studies of long-term opioid therapy in chronic pain patients (32-50%) [4, 7, 19] . However, it should be noted that these studies were generally conducted in the real-world setting and typically had a duration of approximately 1 year, longer than that in the current analysis. Incorporating some study methodologies (e.g., specified patient selection criteria, risk stratification, monitoring) into routine clinical practice may improve outcomes, a notion that is complemented by the increasing efforts to integrate rigorous risk evaluation and mitigation strategy programs for patients on chronic opioid therapy into routine clinical practice.
Conclusions
In this population of patients with no recent history (≤5 years prior to study start) of substance abuse and under structured care administering opioids for chronic pain, including BTP, the incidence of aberrant drug-related behaviors was statistically similar between fentanyl buccal tablet and traditional short-acting opioids for BTP over the 12-week open-label treatment period. Pretreatment risk assessment may be helpful in guiding the appropriate clinical use of these medications, but further study is required.
